We have previously reported that overexpression of the melanoma differentiation-associated gene -7 (mda-7) using a replicationdefective adenovirus (Ad-mda7), results in tumor-specific growth suppression and induction of apoptosis in wide variety of cancer cells. In the present study, we investigated the antitumor activity of Ad-mda7 and the underlying mechanism in human prostate cancer cells and normal prostate epithelial cells. Overexpression of MDA-7 induced significant (P ¼ .001) suppression of cell growth and apoptosis in prostate cancer cells (DU 145, LNCaP,. In normal prostate epithelial cells (PrEC) some degree of growth inhibition but not apoptosis was observed. However, the inhibitory effects in normal cells were less compared to tumor cells. Growth inhibitory effects were mediated by the intracellular and not by extracellular MDA-7 protein. Molecular effectors that are involved in Ad-mda7-mediated tumor killing included activation of the caspase cascade, and the induction of G2 phase cell cycle arrest through the inhibition of Cdc25C pathway. These results demonstrate the mechanisms by which Ad-mda7 exerts its antitumor activity in human prostate cancer cells. The antitumor activity combined with previously reported antiangiogenic and proimmune properties of Ad-mda7 can serve as a potential therapeutic agent for treatment of primary and disseminated prostate cancer.
T he melanoma differentiation-associated gene 7 (mda-7) 1 encodes a protein with a predicted size of 23.8 kDa containing 206 amino acids. 2 The mda-7 gene previously described as a novel tumor suppressor gene has recently been identified as interleukin family member IL-24. 3, 4 However, unlike most other interleukins overexpression of MDA-7/IL-24 using a replication-defective adenovirus results in growth suppression and induction of apoptosis in a broad range of cancer cell types both in vitro and in vivo. 1, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, the induction of apoptosis is tumor selective with minimal to no cytotoxicity observed in normal human cells indicating mda-7 may be an effective therapeutic agent for cancer treatment. 17 The mechanism by which MDA-7 mediates its tumor-suppressive effects remains unclear. Previous studies by us and others have demonstrated that MDA-7 mediated its antitumor activity by activation of the caspase cascade, changes in the ratio of proapoptotic to antiapoptotic proteins, an increase in cells in the G 2 /M cell-cycle phase or a combination of these activities. 5, 7, 8, 10, 11 Additional mechanisms for MDA-7-mediated cell killing include activation of PKR, 18 activation of p38 MAPK pathway, 19 activation of UPR stress response, 20 inhibition of PI3K survival signaling, 21 and activation of Fas/FasL signaling pathway. 13 Thus, MDA-7 is a potent tumor-suppressing agent that exerts its tumor-suppressive effects via multiple pathways in different tumor types. 22 Although the upstream molecular effectors utilized by mda-7 vary among tumor cell types, the pathways clearly converge downstream at the level of mitochondria/ER disruption leading to cell death.
Although the tumor-suppressive function of MDA-7 has been studied in a wide variety of cancer cells, information regarding the function of the mda-7 gene and its downstream pathways in human prostate cancer cells is limited. In a recent study, Lebedeva et al, 23 showed MDA-7-mediated inhibition of prostate cancer cells involved regulation of antiapoptotic proteins, Bcl-2 and Bcl-XL. We therefore tested the tumor-suppressive activity of MDA-7 in prostate cancer cells in vitro and the underlying mechanism of cell killing. In the present study, we demonstrate that Ad-mda7 induces suppression of cell growth and apoptosis selectively in prostate cancer cells through activation of the caspase cascade, the JNK pathway; and the induction of G2 phase cell-cycle arrest through inhibition of the Cdc25C pathway. Furthermore, MDA-7-mediated cell killing was observed to occur via the intrinsic pathway and not via the extrinsic pathway. These results defined the mechanism by which Ad-mda7 exerts its effect in human prostate cancer cells. Combining the antitumor activity of MDA-7 with the previously reported antiangiogenic and proimmune properties makes MDA-7 an ideal gene therapeutic candidate for treatment of primary and disseminated cancers such as prostate cancer.
Materials and methods

Cell lines and cell culture
The human prostate cancer cell lines DU 145, LNCaP, and PC-3 were obtained from American Type Culture Collection (ATCC; Rockville, MD) and grown in RPMI-1640 medium with 10% fetal bovine serum, antibiotics and L-glutamine (GIBCO-BRL, Grand Island, NY). The normal prostate epithelial cell line (PrEC) was obtained from Clonetics (San Diego, CA) and grown in PrEBM medium with supplements according to the supplier's instructions.
Virus construction and transduction efficiency
Construction and production of the replication-deficient adenoviral (Ad5) vector carrying the mda-7 or luciferase (luc) gene has been previously described. 7, 8 Preliminary experiments using an adenoviral vector encoding green fluorescent protein (Ad-GFP) showed that an adenovirus dose delivered at 3000 viral particles per cell (vp/cell) can infect more than 93.4% of DU 145 and PC-3 cells, 76.2% of LNCaP cells, and 82% of PrEC cells (data not shown). Note that 3000 vp is equivalent to approximately 100 PFU and is within the subtoxic dose of the virus. Therefore, in all subsequent experiments cells were treated with Ad-mda7 or Ad-luc at 3000 vp/cell.
Cell proliferation assay
All of the cell lines were plated in six-well tissue culture plates at a density of 1 Â 10 5 cells/well. Tumor cells were then treated with Ad-mda7 or Ad-luc. Cells treated with 0.1 M phosphate-buffered saline (PBS) served as a mock control. Cells in each treatment group were plated in triplicate and cultured for 4 days. Then, at designated time points, cells were harvested via trypsinization and stained with 0.4% trypan blue (GIBCO-BRL, Grand Island, NY) to reveal dead cells. Viable cells were then counted using a hemocytometer as previously described. 7, 8 For PC-3 cells additional experiments were carried out that included time-course (days 4,5, and 6) experiments and dose-dependent experiments (3000, 5000, and 10,000 vp). The effect of MDA-7 on PC-3 cells was determined by viability assay as described above.
For experiments testing the effect of extracellular secreted MDA-7 protein on prostate cancer cells, cancer cells (5 Â 10 5 /well) were treated with Ad-luc or Ad-mda7. After 6 hours, culture medium was replaced with fresh medium and incubated overnight. Conditioned tissue culture medium was collected 48 hours after treatment and added onto a fresh batch of cancer cells and cell viability was determined on day 4. An aliquot of the conditioned medium was tested for secreted MDA-7 protein as previously described. 9
Annexin-V assay
To test whether MDA-7 expression results in apoptosis, tumor cells and normal cells were plated in six-well plates and were treated with PBS, Ad-luc or Ad-mda7. Cells were collected at 72 hours after treatment and stained with Annexin-V (Pharmingen, San Diego, CA) as previously described. 7 The percentage of Annexin-V positive cells were analyzed by flow cytometry.
Cell-cycle analysis
To determine the effect of Ad-mda7 on cell cycle, cells were seeded in 10-cm culture dishes (5-10 Â 10 5 cells/dish) and treated with Ad-mda7, Ad-luc or treated with 0.1 M PBS. At specific times after treatment, cells were harvested via trypsinization, washed once with ice-cold 0.1 M PBS, fixed with 70% ethanol and stored at À201C. Cells were then washed twice with ice-cold 0.1 M PBS and treated with RNase (30 minutes at 371C, 500 units/ml; Sigma Chemicals, St Louis, MO), and DNA was stained with propidium iodide (PI) (50 mg/ml; Boehringer Mannheim, Indianapolis, IN). The cell-cycle phases were analyzed using a fluorescent activated cell sorter (EPICS XL-MCL, Beckman Coulter, Inc., Fullerton, CA).
Immunoblot analysis
Tumor cells (DU 145, and LNCaP) treated with Ad-mda7, Ad-luc, or PBS were harvested at 72 hours after treatment and cell extracts were prepared for Western blot analysis as previously described. 7 For PC-3 cells, cell lysates were prepared on days 4 and 5 after treatment. The following antibodies were used as primary antibodies at appropriate dilutions: Anti-MDA-7 antibody (2.2 mg/ml; Introgen Therapeutics, Inc., Houston, TX); caspase-3 (0.13 mg/ml) and PARP (0.3 mg/ml; Pharmingen, San Diego, CA); cyclin A (0.5 mg/ml), b-actin (0.6 mg/ml; Sigma Chemicals, St Louis, MO); Chk1 (0.5 mg/ml), Cdc2 (0.1 mg/ml), phosphospecific-p38MAPK (0.04 mg/ ml), phosphospecific-JNK (0.4 mg/ml), phosphospecific-STAT3 (0.1 mg/ml; Santa Cruz Biotechnology, Santa Cruz, CA); phosphospecific-STAT1 (1.5 mg/ml), Cdc25C (0.2 mg/ml; Cell Signaling Technology, Inc., Boston, MA); MDA-7 induces apoptosis in prostate cancer Y Saito et al cyclin B1 (1 mg/ml; Lab Vision Corp., Fremont, CA); Chk2 (0.5 mg/ml; Novus Biologicals, Littleton, CO).
Statistical analysis
Student's t-test and ANOVA were used to calculate the statistical significance of the experimental results. The significance level was set at Po.05.
Results
MDA-7 expression following Ad-mda7 treatment in human prostate cancer and epithelial cells
To detect exogenous MDA-7 expression in cells, DU 145, LNCaP, PC-3, and PrEC cells were grown in six-well tissue culture plates (1 Â 10 5 cells/well) and treated with Ad-mda7 and Ad-luc. Cells treated with PBS served as negative controls. At 24, 48, and 72 hours after infection, cell lysates were prepared and evaluated for protein expression by Western blot analysis. MDA-7 expression was detected in all cell lines treated with Ad-mda7 ( Fig  1a) compared to cells that were treated with PBS and with Ad-luc. MDA-7 protein expression was observed to be time dependent with maximum expression observed between 48 and 72 hours. No endogenous MDA-7 expression was detected in the cell lines tested.
Inhibition of cell proliferation in prostate cancer cells due to overexpression of MDA-7
To determine the effect of Ad-mda7 treatment on cell proliferation, tumor cells (DU 145, LNCaP, and PC-3) and normal cells (PrEC) were treated with PBS, with Adluc, or with Ad-mda7. Cells were harvested at various time points after treatment and analyzed for cell viability. A significant inhibition of tumor cell proliferation (P ¼ o.01) was observed starting from day 3 in all the cell lines treated with Ad-mda7 when compared with that in control cells treated with Ad-luc or treated with PBS ( Fig 1b) . The inhibitory effect was observed to be more prominent in LNCaP and DU 145 cells than in PC-3 cells. However, in PC-3 cells MDA-7-mediated inhibitory effect was profound and more significant at later time points starting from day 4 (Fig 1c) . Furthermore, the inhibitory MDA-7 induces apoptosis in prostate cancer Y Saito et al effect in PC-3 cells was dose-dependent with maximal inhibition occurring at concentrations higher than that used in the present study (Fig 1d) . These results suggest that sensitization of human prostate tumor cells to MDA-7 varies and is dose-dependent. Surprisingly in PrEC cells, MDA-7 appeared to exert some degree of inhibition on cell proliferation. However, the inhibitory effect did not significantly alter or increase at later time points (days 5 and 6) when compared to PC-3 cells (data not shown). In contrast to our findings on the effect of Ad-mda7 on normal prostate cells, Lebedeva et al, 23 showed no inhibitory effect of normal prostate cells to Ad-mda7 even when tested up to day 15. The difference in the results between the two studies is not clear. One possibility is the difference in the normal cell line used.
Number of Viable Cells
Another possibility is differences in the experimental conditions. Whatever the differences might be, it is evident from the two studies that Ad-mda7 selectively inhibits prostate cancer cells and not normal prostate cells. Additional evidence provided is the increased number of Ad-mda7-treated tumor cells undergoing apoptosis but not normal cells (see below).
Induction of apoptosis in prostate cancer cells due to overexpression of MDA-7
To determine whether treatment with Ad-mda7 induced apoptosis, cells treated with Ad-mda7, with Ad-luc, or with PBS were subjected to Annexin-V assay. Tumor cells (DU 145, LNCaP, PC-3) treated with Ad-mda7 demonstrated an increase in the number of Annexin-V positive cells, an indicator of apoptosis when compared to cells that were treated with Ad-luc or with PBS (P ¼ o.05; Fig 2) . However, the number of apoptotic cells (12-28%) varied between the tumor cell lines. In contrast, normal cells (PrEC) treated with Ad-mda7 (2.8%) did not demonstrate a significant increase in the number of Annexin-V positive cells when compared to PBS (1.5%) or Ad-luc (1.43%) treated cells. To further confirm these results, cells were stained with Hoechst 33258 at 72 hours after infection. Tumor cells, not normal cells treated with Ad-mda7, demonstrated condensed and fragmented nuclei, an indicator of apoptosis (data not shown). No changes were observed in cells treated with Ad-luc. In agreement with our results is the report by Lebedeva et al. 23 These results indicate that MDA-7 selectively inhibit tumor cells but not normal cells by inducing apoptosis.
Induction of G2 cell-cycle arrest due to overexpression of MDA-7
To determine whether MDA-7 is capable of inducing G2/ M cell-cycle arrest in prostate cancer cells, as reported in previous studies of human lung, breast and melanoma cancer cell lines, 7, 9, 11 cell-cycle phases were analyzed by flow cytometry. Cell-cycle analysis demonstrated a significant increase in the number (10-40%; P ¼ o.05) of tumor cells in the G2/M population at 72 hours after treatment with Ad-mda7 as compared with tumor cells treated with Ad-luc or with PBS ( Fig 3) . Unlike tumor cells, normal cells treated with Ad-mda7 demonstrated no significant increase in the number of cells (o5%) in G2/ M phase when compared to control cells that were treated with PBS or Ad-luc. These results demonstrate that MDA-7 selectively affected tumor cells but not normal cells.
G2 cell-cycle arrest by MDA-7 is associated with downregulation of Cdc25C
To investigate the mechanism by which MDA-7 significantly induces G2 arrest in prostate cancer cells, we evaluated proteins related to the G2/M cell cycle checkpoints by Western blot analysis. Ad-mda7-treated DU 145 and LNCaP cells demonstrated reduced expression of both phosphorylated and nonphosphorylated Cdc25C and decreased expression of Chk1 and Chk2, and cyclin B1 proteins that are associated with G2/M phase (Fig 4a and b) . No significant changes in these proteins were observed in cells that were treated with PBS or treated with Ad-luc. The examination of Cdc2 demonstrated decrease in Cdc2 expression in LNCaP cells but not in DU 145 cells treated with Ad-mda7. Furthermore, cyclin A that is related with G1/S cell-cycle checkpoint was evaluated. Cyclin A was observed to be reduced in DU 145 but not in LNCaP cells treated with Ad-mda7. These results indicate that MDA-7 induces G2 cell-cycle arrest by downregulating G2/M-related proteins and are consistent with our cell-cycle analysis described above. an increase in the phosphorylated form of STAT1 (pSTAT-1) and JNK (pJNK), in both DU 145 and LNCaP cells treated with Ad-mda7 compared to cells that were treated with PBS, and Ad-luc (Fig 5a and b) . In contrast, a decrease in the phosphorylated form of STAT-3 (pSTAT-3) was observed in both tumor cell lines treated with Ad-mda7. Activation of JNK by MDA-7 is not surprising and is in agreement with the findings of Kawabe et al, 24 who demonstrated MDA-7-mediated JNK activation in lung cancer cells. No significant change in the expression levels of p38MAPK was observed in both DU 145 and LNCaP cells when treated with Ad-mda7 compared to those treated with PBS and Ad-luc. Analysis for PKR that has previously been shown to be activated by MDA-7 in lung cancer cells 18 demonstrated no significant change in PKR expression in the tumors cells treated with Ad-mda7 compared to control cells. Further analysis of the downstream targets, namely caspases, revealed activation of caspase-9, caspase-3, and PARP at 72 hours after Ad-mda7 treatment in both DU 145 and LNCaP cells (Fig 5a and b) .
To determine whether similar signaling molecules are activated in PC-3 following MDA-7 expression, cell lysates from Ad-mda7-treated cells were analyzed and compared to cell lysates from PBS and Ad-luc-treated cells. PC-3 cells unlike for DU 145 and LNCaP were analyzed on days 4 and 5 since they exhibited delayed sensitization to MDA-7. Activation of caspase-9 and caspase-3 was observed in Ad-mda7-treated PC-3 cells compared to PBS and Ad-luc-treated cells on days 4 and 5 (Fig 5c) . A slight decrease in total PARP was observed indicating cleavage. Activation of p38MAPK and pJNK albeit less was also observed in Ad-mda7-treated cells compared to PBS and Ad-luc-treated cells. However, no significant change in PKR was observed. The inability to detect STAT-3 in these cells is not surprising as they are deficient in STAT-3. 25, 26 These results demonstrate that MDA-7-mediated apoptosis in prostate cancer cells involves activation of various proapoptotic-signaling molecules and is independent of PKR.
MDA-7-mediated killing is mediated via the intrinsic pathway
The receptors for MDA-7 have been reported. 3, 4 Furthermore, we and others have previously demonstrated the secretion of MDA-7 protein raising the possibility that the observed cell killing can be mediated by the intracellular (intrinsic) mda-7 pathway or by the extracellular (extrinsic) mda-7 pathway. 3, 4, 9, 11 To test this possibility, we first tested for the receptor expression in the three prostate tumor cell lines using receptor-specific primers and antibodies for reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot analyses. RT-PCR analysis showed expression of the individual receptor subunits in the tumor cells (data not shown). Western blotting analysis demonstrated IL-20R1 and IL-22R1 expression in all three tumor cell lines (Fig 6a) . However, the level of expression varied among the cell lines. The human keratinocyte HACAT cell line that has previously been shown to be receptor positive was used as positive control in these experiments.
We next tested the effect of secreted MDA-7 protein contained in the conditioned medium on cell proliferation. For this purpose, conditioned tissue culture medium from Ad-luc-and Ad-mda7-treated cells were collected and added onto a fresh batch of tumor cells. No significant change in cell proliferation was observed when conditioned medium from Ad-luc-or Ad-mda7-treated cells were added (Fig 6b) . Lack of inhibitory effect on cell proliferation due to absence of MDA-7 protein in the conditioned medium was ruled out by Western blotting analysis (upper panel; Fig 6b) . These results suggest that the observed inhibitory effect in Ad-mda7-treated prostate tumor cells occurs via the intrinsic pathway and not via the extrinsic pathway. Our results are in concurrence 
Discussion
The tumor suppressor gene mda-7 has recently been reported to inhibit growth and induce apoptosis in various cancer cells, including melanoma, lung, and breast cancer. 5, [7] [8] [9] 11, 15 The mechanisms underlying the anticancer activity of the mda-7 gene are still unclear; however, induction of apoptosis by Ad-mda7 in a p53independent manner has been demonstrated both in vitro and in vivo. 5, [7] [8] [9] 11, 22, 24 In the present study, we expanded on these observations and evaluated the effect of overexpression of Ad-mda7 on growth, cell-cycle kinetics, and survival of prostate cancer cells and normal prostate epithelial cells. We demonstrated that Ad-mda7 does not significantly alter cell growth, cell-cycle kinetics, or survival in normal prostate epithelial cells, although in prostate cancer cells, growth is significantly suppressed, G 2 cell-cycle arrest is induced, and apoptosis is selectively induced via the caspase cascade. The Ad-mda7-mediated growth suppression in PC-3 cells, as determined by viability assay, appeared less when compared to DU 145 and LNCaP cells. The possibility that the difference in sensitivity of PC-3 cells to Ad-mda7 was due to inefficient adenoviral transduction was ruled out by testing for transduction efficiency. More than 80% of cells were transfected as indicated by GFP-positive cells and is in agreement with previous report. 23 Failure to express the transgene was also ruled out by Western blot analyses that showed MDA-7 expression levels comparable to that observed in DU 145 and LNCaP cells. However, it is possible that it may have been too early for MDA-7 to induce significant suppression in PC-3 cells at day 4. Examination of Ad-mda7-treated PC-3 cells at later time points (days 5 and 6) demonstrated increased sensitivity that resulted in increased apoptosis. Additionally, increasing the viral dose resulted in increased growth inhibition and apoptosis in PC-3 cells. These results suggest that PC-3 cells are sensitive to MDA-7 and require longer time or higher dose to show sensitization. The normal PrEC cells unlike PC-3 cells did not show any additional increase in sensitivity when tested at later time points suggesting that normal cells are resistant to MDA-7-mediated killing (data not shown). Our results are in agreement with the report of Lebedeva et al, 23 who recently showed normal prostate epithelial cells to be resistant to MDA-7. These results suggest that Ad-mda7 selectively inhibit prostate cancer sparing normal cells.
Although our data showed significant suppression of prostate cancer cells after Ad-mda7 treatment, the inhibitory effect was observed to occur at later time points starting at day 3. This is in contrast to the inhibitory activity observed in lung cancer cells that starts from day 2 after Ad-mda7 treatment. 7 Delayed antitumor activity of MDA-7 has also been observed in melanoma cells. 5, 10 These results indicate that the cytotoxic effects of MDA-7 vary among tumor cell types. The exact cause for the delayed antitumor activity of MDA-7 in prostate and melanoma cells is not known. One possibility for the delayed antitumor activity of MDA-7 is probably due to the expression of the transcription factor, nuclear factor kappa B (NF-kB) that functions as an antiapoptotic molecule and protect cells from death. 28, 29 Expression of high levels of NF-kB has previously been reported in both prostate cancer and melanoma. 28, 30 Based on these reports, we speculate that the observed delay for MDA-7 to exert its antitumor activity in prostate cancer cells is the time required to override the expression of NF-kB. Alternatively, the delay could be the time taken to override the expression of antiapoptotic proteins. 23 In a recent study, modulation of antiapoptotic proteins, Bcl-2 and Bcl-XL was shown after MDA-7 expression. However, in the present study we did not observe any significant change in the expression of these proapoptotic proteins. The differences in the results between the two studies are not well understood and remain to be investigated. One possibility could be differences in the experimental conditions followed. Unlike in the present study, Lebedeva et al 23 analyzed the inhibitory effects at late time points beyond days 6 and 7 at which time additional molecules may be regulated. Alternatively, the differences in the virus dose used in the two studies could explain the differences. We are currently investigating this possibility in the laboratory.
Previous studies have demonstrated induction of G2/M cell-cycle arrest by MDA-7. 5,7-9,11 Based on these reports, we investigated the mechanism by which MDA-7 induces G2/M cell-cycle arrest in prostate cancer cells. In the present study, we clearly demonstrated that G 2 arrest occurs through the inhibition of Chk1 and Chk2 that are activated during DNA damage or inhibition of DNA replication and by inhibition of the phosphorylation of the Cdc25C on Serine-216. Cdc25C has previously been shown to play an important role in the regulation of G2 checkpoint. 31 Further, p53 status might be related to the enhancement of G2 arrest by MDA-7, because p21 and p27, which are activated at G1 arrest, 32 were activated in LNCaP cells containing wild-type p53 but not in DU 145 cells containing mutant-type p53 (data not shown). Furthermore, the percentage of cells at G2 phase in LNCaP cells was significantly lower than in DU 145 cells. PKR might have also enhanced G2 arrest. 33 However, a role for PKR-mediated G2 arrest in the present study was eliminated since PKR was not significantly activated in two of the three tumor cell lines tested. Our observation on the expression of cell-cycle-associated proteins, including cdc2, and cyclin B1 at G2/M arrest are consistent with that previously reported. 34 We next examined the signaling mechanism for MDA-7-mediated apoptosis. Studies by us and others have demonstrated activation of multiple signaling pathways by MDA-7 in a spectrum of cancer cells resulting in the activation of the caspase cascade and induction of apoptosis. [6] [7] [8] [9] 11 In lung cancer cells, activation of PKR was shown to be important for MDA-7-mediated cell killing. 18 In melanoma, p38MAPK was shown to be important for MDA-7-mediated antitumor activity. 19 Inhibition of PKR or p38MAPK expression resulted in loss of the inhibitory activity of MDA-7 in lung cancer cells and melanoma, respectively. However, expression of MDA-7 resulted in no significant increase in PKR expression in the three prostate cancer cells tested. Similarly, analysis for p38MAPK expression demonstrated no significant change after MDA-7 expression. Thus, unlike lung cancer cells and melanoma, MDA-7induced cell death in prostate cancer cells is independent of PKR and p38MAPK. Since activation of JNK was observed in all the cell lines, we speculated that JNK may play an important role in MDA-7-mediated cell killing in prostate cancer cells. A role for JNK in mediating apoptotic cell death has previously been documented. 24 Preliminary studies using a JNK-specific inhibitor resulted in a reduction in the MDA-7-mediated antitumor activity (data not shown). Demonstration of activation of the STAT-1 and the caspase cascade by MDA-7 is in agreement with previous studies. 7, 18, 35 The activation of STAT1 and STAT3 in tumors can play opposite roles. 36 STAT3 has been shown to promote oncogenesis. In contrast, STAT1 suppresses oncogenesis. Our present data demonstrating the activation of STAT-1 by MDA-7 supports this observation. Thus, it appears that MDA-7mediated tumor killing in prostate cancer cells involves activation of the JNK pathway resulting in the activation of the caspase cascade. However, additional studies are warranted and are currently under investigation in the laboratory.
The possibility that the observed tumor cell killing is mediated via the extrinsic pathway was next investigated. The receptor for MDA-7 has been reported. Furthermore, receptor expression in prostate cancer cells at the mRNA level has recently been reported. 26, 37 Therefore, to test whether MDA-7-mediated killing occurred via the extrinsic pathway we first analyzed for receptor expression at the mRNA level and at the protein level. Analysis for receptor mRNA expression showed that prostate cancer cells expressed the receptors (data not shown), which is in agreement with the recent report by Lebedeva et al. 23 However, since mRNA expression does not always translate into protein expression, we also tested for receptor expression at the protein level. MDA-7 receptor expression was observed in all three prostate cancer cell lines and correlated with mRNA expression. This is the first report showing MDA-7 receptor expression at the protein level. Based on our results, we next tested the effect of MDA-7 protein on cell proliferation. Addition of conditioned medium containing MDA-7 protein did not result in significant growth inhibition. Our results suggest that the observed MDA-7-mediated growth inhibition is primarily mediated via the intrinsic pathway and is in agreement with our previous study. 20, 27 However additional studies are warranted examining the effects of extracellular MDA-7 protein on prostate tumor cell death.
In summary, the present study demonstrates that adenoviral-mediated transfer of mda-7 selectively induces apoptosis and cell-cycle arrest in prostate cancer cells but not in normal cells. Furthermore, MDA-7-mediated growth inhibition and apoptosis occurred mainly via the intrinsic and not extrinsic pathway. The potent antitumor activity combined with the antiangiogenic 38 and antimetastatic 39 properties of MDA-7 makes mda-7 an ideal drug for treatment of primary and metastatic prostate cancer. However, systemic treatment of metastatic prostate cancer with Ad-mda7 is currently limited. Therefore, alternate gene delivery vectors such as nonviral vectors are to be tested. Development and demonstration of systemic delivery of mda-7 using nonviral vectors is an attractive approach for treatment of metastatic cancer. 40 The outcome of such studies will result in the development of a systemic therapeutic strategy for the treatment of prostate cancer and ultimately leading to the clinic.
